NASDAQ · ZVRA
Zevra Therapeutics, Inc.
$10.20-$0.16 (-1.57%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.2% below the high.
Loading market information…
NASDAQ · THRX · USD
Stock price, dividends, earnings
Quote as of Feb 13, 2024, 08:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Theseus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Theseus Pharmaceuticals, Inc.’s forward annual dividend is $1.00 per share, paid quarterly. The forward yield is 24.6% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Theseus Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2022 |
|---|
| May 12, 2022 |
| -$0.27-8.0% vs estimate |
| $0.00 |
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.20-$0.16 (-1.57%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.2% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$7.12$0.00 (0.0%)
F-star Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.88-$0.08 (-8.0%)
Selecta Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.72% below the high.
$3.33-$0.17 (-4.73%)
LENZ Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.65% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
